ARK Genomic Revolution ETF
ARKG
300 hedge funds and large institutions have $619M invested in ARK Genomic Revolution ETF in 2023 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 68 increasing their positions, 97 reducing their positions, and 41 closing their positions.
43% more capital invested
Capital invested by funds: $433M → $619M (+$186M)
34% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 41
4% more funds holding
Funds holding: 288 → 300 (+12)
3.77% more ownership
Funds ownership: 25.1% → 28.87% (+3.8%)
24% less call options, than puts
Call options by funds: $68.2M | Put options by funds: $90.1M
30% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 97
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMEA
Main Management ETF Advisors
San Francisco,
California
|
+$57.7M |
| 2 |
MM
Main Management
San Francisco,
California
|
+$18.4M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$17.6M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$16.7M |
| 5 |
Goldman Sachs
New York
|
+$12.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$43.7M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$13.6M |
| 3 |
CCM
Cinctive Capital Management
New York
|
-$5.57M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.5M |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2.23M |
ARKG Hedge Fund Activity: Q4 2023 in Review
300 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q4 2023, worth a combined $619M — up 43% from $433M a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new ARKG positions and 41 closed out — a net gain of 14 holders — while 68 added to existing stakes and 97 trimmed.
The largest buyer was Main Management ETF Advisors, adding an estimated $57.7M. The largest seller was Morgan Stanley, cutting an estimated $43.7M.
- 300 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q4 2023, up from 288 in Q3 2023.
- Funds reported $619M of ARK Genomic Revolution ETF stock for Q4 2023, up 43% quarter-over-quarter.
- 55 funds opened new ARK Genomic Revolution ETF positions in Q4 2023 and 41 closed out, a net change of +14 holders.
- The largest ARK Genomic Revolution ETF buyer in Q4 2023 was Main Management ETF Advisors, an estimated $57.7M added.
- The largest ARK Genomic Revolution ETF seller in Q4 2023 was Morgan Stanley, an estimated $43.7M sold.
Based on aggregated 13F filings for Q4 2023.